Ebolavirus is a pathogen capable of causing highly lethal haemorrhagic fever in humans. The 17 envelope-displayed viral glycoprotein is the primary target of humoral immunity induced by both 18 natural exposure and vaccination. The epitopes targeted by B cells have been thoroughly 19 characterised by functional and structural analyses of the glycoprotein, GP, yet there is a paucity of 20 information regarding the cellular immune response to Ebolavirus. To date, no T cell epitopes in the 21 glycoprotein have been characterised in detail in humans. 22 48 licensure proceed, detailed characterisation of immunity to the virus contribute to our 49 understanding of the potential application of vaccines in diverse populations. 50 51 4 52
A recent Phase I clinical trial of a heterologous prime-boost vaccination regime with viral vectors 23 encoding filovirus antigens elicited strong humoral and T cell responses in vaccinees. Using samples 24 from this trial, the most frequently recognised peptide pools were studied in more detail to identify 25 the minimal epitopes recognised by antigen-specific T cells and associated HLA-restrictions.
26
Using IFN ELISPOT and flow cytometry, we characterised nine highly immunogenic T cell epitopes 27 located on both the GP 1 and GP 2 subunits of the Ebolavirus GP. Epitope mapping revealed the 28 location of these epitopes as presented on the mature virion. HLA-typing on all participants, 29 combined with in silico epitope analysis, determined the likely MHC class I restriction elements.
30
Thirteen HLA-A and -B alleles were predicted to present the identified epitopes, suggesting 31 promiscuous recognition and induction of a broad immune response.
32
The glycoprotein of Ebolavirus is highly immunogenic, inducing both CD4 + and CD8 + T cell responses 33 and we have shown here for the first time that these responses are associated with multiple HLA 34 types. Delivery of this antigen using a heterologous prime-boost approach with ChAd3 and MVA is 35 likely to be highly immunogenic in genetically diverse human populations, due to the induction of 36 responses against multiple immunodominant epitopes.
37
Author Summary (150-200 words) 38 The West African Ebolavirus epidemic in 2013-2016 claimed more than 11,000 lives, eclipsing all 39 previously recorded outbreaks combined. Understanding the mechanisms of host-pathogen 40 interactions informs rational vaccine design. B cell epitopes have been described extensively through 41 the characterisation of monoclonal antibodies from survivors of Ebolavirus disease. Despite a clear 42 role for cellular immunity in survival of Ebolavirus disease, data relating to minimal T cell epitopes in 43 the glycoprotein has so far only been obtained in murine. This study describes the first identification 44 of human T cell epitopes in the surface glycoprotein of the Ebolavirus. These epitopes have been 45 identified using samples from a clinical trial of viral vectored vaccines against the Zaire Ebolavirus 46 undertaken during the 2013-2016 West African outbreak. We also describe the recognition of these 47 epitopes through multiple HLA alleles. As efforts to progress a vaccine against Ebola towards Introduction 53
The West African Ebolavirus epidemic that began in Guinea in December 2013 claimed more than 54 11,000 lives, eclipsing all previously recorded outbreaks combined [1, 2] . The aetiological agent of 55 this outbreak, Zaire ebolavirus (EBOV), is one of five species within the Ebolavirus genus of the 56 Filoviridae family [3] . Three other members of this genus; Sudan ebolavirus (SUDV), Tai Forest 57 ebolavirus (TAFV) and Bundibugyo ebolavirus (BDBV), are also pathogenic in humans [4] . The fifth 58 member, Reston ebolavirus (RESTV), is not associated with disease in humans but has been isolated 59 from non-human primates (NHP) and swine [5, 6] . While the case fatality rate of the West African 60 epidemic (2013) (2014) (2015) (2016) was estimated at 40%, it has been as high as 90% in previous outbreaks [1] . Figure 1A ). The strongest responses were seen to pools 1.1 and 2.2, 118 corresponding to the N-terminus of GP 1 and C-terminus of GP 2 , with GM responses of 237 and 164 119 SFC respectively. The peptides constituting the signal peptide (SP), as well as 1.5 and 1.7 pools gave 120 positive responses in less than 40% of participants and were not assessed further. ELISpot responses to individual peptides 133 The seven most immunogenic pools were retested by IFN ELISpot using frozen PBMC selected from 134 clinical trial participants that responded strongly in the preliminary assay, subject to sample 135 availability. Each pool was deconvoluted to the constituent peptides (20-21 peptides per pool) using 136 PBMC from between 6 and 8 vaccinees. In the seven pools tested, at least one immunodominant 137 peptide was identified in each, and in some pools, more than one immunogenic region was observed 138 suggesting multiple epitopes ( Figure 1B and Figure 2 ). Following deconvolution of the responses to 139 the peptide pools, ten of the most immunodominant peptides and regions were selected based on 140 the strength of the ELISPOT response and sample availability, and a library of 94 nonamers was 141 produced. A summary of the nonamers is shown in Table 1 and sequences for the individual 142 nonamers are shown in Supplementary Table 2 . Thirteen of the nonamers elicited positive responses in more than one participant (8, 9, 15, 26, 31, 150 38, 39, 47,48, 55, 65, 92, 93 and 94) and responses to the nonamers are shown in Figure 3A . Where 151 nonamers that gave a positive response were adjacent, we subsequently considered these to be part 152 of a single epitope. These putative epitopes are displayed as nine colour coded regions. The 153 locations of these putative epitopes were then displayed diagrammatically on the primary 154 glycoprotein structure ( Figure 3B ). (8,9, 15, 26, 31, 38, 39, 47,48, 55, 65, 92, 93 and 94) 
EBOV GP Epitope Sequence and Location in Primary Structure

167
The 13 immunogenic nonamers formed nine discrete putative epitopes ( Table 2 ). The sequences of 168 the constituent nonamers were used to identify the location of the epitopes in the primary structure 169 of EBOV GP ( Figure 3B ). The first three are located in an epitope-rich 40 amino acid stretch in the N-170 terminal half of GP 1 . The first epitope is 12 amino acids long and comprised of the nonamers 6, 8 171 and 9 although nonamer 7 elicited no T cell activity ( Figure 3B ). The second epitope is situated 172 immediately adjacent to the first and is comprised of nonamer 15 alone. No immunogenicity was 173 detected with nonamers 11-14, which span the junction of the two epitopes. The third epitope is 174 located nine residues downstream. A fourth epitope, constituting nonamer 31 alone, corresponds to 175 residues 164-172. These four epitopes are all involved in the formation of the GP 1 head structure in 176 the mature GP (Supplementary figure 1) . Epitopes five and six are located within the glycan cap 177 region of GP 1 . No epitopes were identified near the C-terminus of GP 1 which corresponds to pools 178 1.5, 1.6 and 1.7 (pools 1.5 and 1.7 were excluded from the epitope analysis at an earlier stage due to 179 poor immunogenicity). Further analysis of the location of the epitopes on the structure of the 180 glycoprotein is included in the Supplementary information ( Supplementary Figure 1 ). We identified three epitopes in the GP 2 protein, the first of which is 9 amino acids long formed by 185 nonamer 55 and incorporates part of the internal fusion loop (7). The second epitope is comprised of 186 the singular nonamer 65, and the final epitope represents the terminal ten amino acids of the GP 187 which form part of the transmembrane domain and cytosolic tail. The other species within the genus 188
181
Ebolavirus that causes significant outbreaks in humans is SUDV and therefore we determined 189 sequence identity between the identified EBOV GP epitopes and the corresponding sequences in 190 SUDV GP. Homology was at least 50% for all epitopes with epitopes 2, 3 and 4 being 100% identical 191 (Table 2) . High-resolution HLA typing was performed on all participants ( Supplementary Table 3 ) and MHC 208 Class I alleles were analysed using NetMHCpan (version 3.0) to assign HLA restriction elements from 209 each volunteer to each of the positive peptides. This predicts the binding of the peptide to each of 210 the 3-6 HLA alleles for the volunteer, (2 each of HLA-A, B and C alleles, unless homozygous) and the 211 allele with the strongest predicted binding value as the likely restriction element was determined. A 212 rank score binding value of less than two percent has been shown to recover 95% of previously 213 validated epitopes with higher than 99% specificity. For all epitopes, at least one restriction element 214 from a responding participant was predicted to be a strong binder (Table 3 ) and for four of the 215 epitopes (1, 3, 7 and 9), more than one element was predicted to bind strongly. Of the alleles 216 predicted to bind strongly, nine were HLA-A alleles and five were HLA-B.
217 There were three epitopes where the prediction algorithm gave a poor (rank > 2%) binding 220 prediction for the HLA of some of the responding volunteers. In each case, a shift of a single amino 221 acid produced a strong binding value. In these cases, the assays were repeated and the result 222 reconfirmed (data not shown). An example of this was the epitope TDVPSATKR. Here, 2 volunteers 223 (44 and 96) expressed the HLA-A11:01 allele, yet this was predicted to bind very poorly (rank score 224 18%). The adjacent epitope ATDVPSATK was predicted to bind strongly with this allele and was 225 indeed recognised by three volunteers expressing this allele.
226
To confirm recognition of epitopes through the predicted allele, MHC Class I pentamers were 227 produced for peptide 1 (ATDFPSATK) bound to the HLA-A11:01 MHC molecule and a second for 228 peptide 9 (LFCICKFVF) bound to HLA-A24:02. For the HLA-A11:01 pentamer containing the 229 ATDVPSATK peptide, 0.83% and 0.15% of CD8 + T cells stained positive from donor 044 and 096 230 respectively, while PBMC from a mis-matched volunteer, 066, were negative ( Figure 5A ). Only one 231 volunteer recognising LFCICKFVF had sufficient PBMC remaining for pentamer staining and 0.14% of 232 their CD8 + T cells were pentamer positive ( Figure 5B ). We therefore demonstrated that the in silico 233 prediction of MHC allele binding to epitopes we identified was correct for at least two nonamers. In this study, we identified 13 nonamers in the EBOV glycoprotein that elicit strong cellular 245 responses in vaccinated individuals. When overlaid on to the protein, the nonamers form nine 246 discreet epitopes, ranging in length from 9 to 14 amino acids ( Supplementary Figure 1) 
261
Conservation of epitopes is critical if they are to be of use in future vaccines as alterations to the T 262 cell targets will likely result in diminished efficacy. Initial reports from the West African outbreak 263 indicated that the circulating EBOV was undergoing an increased mutation rate, up to twice that 264 seen in previous outbreaks [47] . Further work subsequently demonstrated that the viral mutation 265 rate was in fact similar to those previously estimated with the majority of nucleotide alterations 266 being either silent or occurring in noncoding regions [48, 49] . The epitopes identified here exhibit a 267 high level of conservation across EBOV strains. The ChAd3 and MVA vectors encode GP from the 268 1976 Mayinga strain, and at the amino acid level, the epitopes are completely conserved in the 2014 269 Makona-Gueckedou strain as well as all intervening strains which were identified (Kikwit 1995 , 270 Gabon 1996 , Gabon 2002 . Most of these epitopes are highly conserved with the related SUDV GP, 271 suggesting that T cells raised in individuals vaccinated with EBOV GP would show cross-reactivity 272 against SUDV GP.
273
Interestingly, three of the epitopes characterised within this study had previously been predicted, in 274 part or completely, by computational and murine studies. The fourth epitope was partially 275 predicted by two different studies and shown to effectively stimulate splenocytes of immunised 276 mice [28, 30, 50] . Epitopes seven and eight were also predicted, the former partially and the later 277 entirely, by several studies [27] [28] [29] . We were also able to confirm the accuracy of the epitope 278 prediction algorithm with pentamers for 2 epitopes, showing that in silico approaches remain a valid 279 strategy to infer MHC restriction.
280
The epitopes identified in this paper are the first human EBOV T cell epitopes in the glycoprotein 281 characterised in detail and build our knowledge about cellular responses to this pathogen.
282
Identification and characterisation of the identified peptides may also aid in future vaccine design.
283
Determining the strongly and weakly immunogenic regions of a target protein could allow vaccine 284 constructs to be truncated or create mosaic inserts for vectors with a limited genomic capacity.
285
Importantly, the finding that this vaccine regime elicits potent cell-mediated immunity in donors 286 with a broad range of HLA types indicates the potential immunogenicity of this approach in 287 genetically diverse populations. Furthermore, dominant epitopes induced by vaccination could be Figure 1A ). All subsequent ELISpot assays were performed 327 using PBMC cryopreserved from the clinical trial and stored in the vapour phase of liquid nitrogen. Epitope HLA-restriction predication 389 MHC Class I alleles were analysed using NetMHCpan (version 3.0) to assign an HLA restriction 390 element from each volunteer to each of the positive peptides. HLA restriction and peptide binding 391 strength was assigned by for each peptide predicting binding to all HLA molecules of the positive 392 volunteer and reporting the lowest percentile rank score and associated HLA molecule. Rank score 393 binding values less than 2% were considered to predict strong binding of an epitope to a HLA allele.
394
This is the value conventionally used to define peptide binders to HLA. At this binding value 95% of 395 validated epitopes are identified at a specificity of > 99% [55] . 412 Bibliography
